Recent investigations have centered on the overlap of glucagon-like peptide-1|GIP|glucagon receptor stimulant therapies and DA communication. While GIP agonists are widely employed for addressing type 2 T2DM, their emerging impacts on reinforcement circuits, specifically influenced by DA pathways, are receiving considerable focus. This article p… Read More